AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01827137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: optional post-ASCT therapy
Study NCT03800095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early palliative care integration
Description: The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
Study NCT02893917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO
Study NCT02893917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT02893917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Given PO
Study NCT00674479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB018424
Description: Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
Study NCT04179552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAAG-OA
Description: Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
Study NCT03001557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 2.5 mg
Description: Lemborexant 2.5 mg tablets
Study NCT03001557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Description: Lemborexant 5 mg tablets
Study NCT03001557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: Lemborexant 10 mg tablets
Study NCT03001557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 15 mg
Description: Lemborexant 5 mg and 10 mg tablets
Study NCT03001557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant-matched placebo
Description: Lemborexant-matched placebo tablets
Study NCT03001557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lemborexant-matched placebo
Description: Lemborexant-matched placebo tablets
Study NCT00466232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
Study NCT00466232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
Study NCT00127634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 24 months, up to 36 months
Study NCT00127634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable Insulin
Description: patient specific dose, injectable, before meals, 24 months, up to 36 months.
Study NCT00127634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: patient specific dose, injectable, as needed, 24 months up to 36 months
Study NCT00127634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: patient specific dose, injectable, as needed, 24 months up to 36 months
Study NCT02655328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample
Study NCT02655328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urine sample
Description: urine sample
Study NCT02855203 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiosurgery (SABR)
Description: 18-20Gy in 1 fraction
Study NCT02855203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at a dose of 200mg IV, 3-weekly will be delivered for a duration of 6 months, commencing 5 days (+/- 3 days) from the last dose of SABR.
Study NCT02646826 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are treated with Placebo tablets
Study NCT02646826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxerol - Dose Level 1
Description: Subjects are treated with the first dose level of Paxerol
Study NCT02646826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxerol - Dose Level 2
Description: Subjects are treated with the second dose level of Paxerol
Study NCT02646826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxerol - Dose Level 3
Description: Subjects are treated with the third dose level of Paxerol
Study NCT01814774 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No treatment (intervention) was administered.
Study NCT02866136 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: VP16, carboplatin
Description: Systemic treatment : Intravenous injections, 2 cycles (21 days)
Study NCT02866136 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: intraarterial injections, 3 to 6 cycles (1 month)
Study NCT04668469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: evaluation of the anti-parasitic medication efficacy Ivermectin (Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with COVID 19 infection
Study NCT04668469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: evaluation of hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care in the treatment of mild/moderate cases with COVID 19 infection
Study NCT04668469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personal protective Measures
Description: evaluation of personal protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, wearing masks, and self-isolation) only as a prophylaxis for health care and or household contacts' from COVID-19 disease
Study NCT04668469 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: personal protective Measures
Description: evaluation of personal protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, wearing masks, and self-isolation) only as a prophylaxis for health care and or household contacts' from COVID-19 disease
Study NCT02763059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
Study NCT02866136 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: VP16, carboplatin, vincristin
Description: Systemic treatment : Intravenous injections, 6 cycles (21 days)
Study NCT02866136 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin + laser day 1 (chemothermotherapy)
Description: Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
Study NCT02763059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: This group receives 1 hour before surgery 4 mg dexamethasone (and another 4 mg 6 hours after the first dose)
Study NCT02763059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group receives 1 hour before surgery placebo.
Study NCT02763059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1000 mg
Description: A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
Study NCT02866136 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laser (local treatment)
Study NCT02763059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen 1000 mg
Description: A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
Study NCT02529917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hemp powder
Description: Hemp powder supplement
Study NCT02529917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Powder
Description: Soy powder supplement
Study NCT03213340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catechin Cohort 1
Description: - 4 capsules taken with water 1 hour prior to meal
Study NCT03213340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curcuminoid Cohort 2
Description: - 2 capsules taken with water 1 hour prior to meal
Study NCT03213340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavonoid Cohort 3
Description: - \~ 1 oz. serving consumed 30 minutes before meal
Study NCT02866136 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: cryoapplication (local treatment)
Study NCT02866136 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: I125 radioactive plaques (local treatment)
Study NCT03452540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000mg DS102 (BID)
Description: Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
Study NCT02056743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP cocktail
Description: Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
Study NCT02056743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine 30mg
Description: Each group administered Fexofenadine 30mg under fasting conditions.
Study NCT02056743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red ginseng
Description: During 4\~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
Study NCT02056743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented-red ginseng
Description: During 4\~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
Study NCT05081908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Multisession radiosurgery (hypofractionated radiotherapy) with Cyberknife
Study NCT02913703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
Study NCT02913703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.
Study NCT02570178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: balance training
Description: Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
Study NCT00976846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer Baxter Xenium XPH 210
Description: High-Flux dialyzer
Study NCT01380353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine patch
Description: Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner \[B\].
Study NCT01045460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated marrow infiltrating lymphocytes
Description: Administered on Days 3 and 4.
Study NCT01045460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Myeloma Vaccine
Description: Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.
Study NCT01045460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered at 2.5 g/m\^2.
Study NCT01045460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administered post cyclophosphamide daily until leukapheresis.
Study NCT01045460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.
Study NCT01045460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2/day given on Days -2 and -1.
Study NCT02866136 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intravitreal Melphalan (local treatment)
Study NCT02824081 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood sample in order to study inflammatory biomarkers and genetics purpose
Study NCT01045460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: Infused on Day 0.
Study NCT04891614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRISM
Description: Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
Study NCT02319200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months
Study NCT02319200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: 4 tablets per day for 36 months
Study NCT01333748 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood collection
Description: blood collection for research quantification of allelic expression in the gene BRCA1.
Study NCT01333748 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: blood collection
Description: blood collection for research quantification of allelic expression in the gene BRCA1.
Study NCT04177706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.
Study NCT04177706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receiving the placebo study medication will receive saline twice per week for four weeks under clinical supervision.
Study NCT00472108 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT)
Study NCT00472108 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Photodynamic Therapy (PDT)
Study NCT00472108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix cream
Study NCT00472108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Study NCT00574808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outreach Facilitation implementing elements of the Chronic Care Model
Description: An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation.
Study NCT01101217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Supplement
Description: in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
Study NCT01101217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo daily for 6 weeks
Study NCT03828032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mannitol injection
Description: Standard mannitol injection to decrease intracranial pressure of patients
Study NCT03828032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection
Description: Standard Hypertonic saline injection to decrease intracranial pressure of patients
Study NCT00642356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa/entacapone
Description: Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
Study NCT00642356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release carbidopa/levodopa
Description: Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
Study NCT00298324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: 1440mg twice daily
Study NCT00298324 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone and Cyclosporine
Description: Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
Study NCT01472640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: 1.8 mg sc QOD
Study NCT01472640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 U sc QOD
Study NCT03488095 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BCI for SLT and BQ Use in Adolescents: A CRT
Description: BCI for SLT and BQ Use in Adolescents: A CRT is aimed towards changing Adolescenst behaviors regarding their SLT and BQ use to as to reduce Oral cancer Burden within population because of this.
Study NCT02144181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT04458636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Oral
Study NCT04458636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral
Study NCT04386369 — intervention group
Intervention type: OTHER
Intervention: Airway pressure release ventilation
Description: Ventilator management strategy
Study NCT00933699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 21 consecutive days
Study NCT01697215 — intervention group
Intervention type: OTHER
Intervention: AirWave
Study NCT00967564 — intervention group
Intervention type: OTHER
Intervention: epidemiologic study
Description: QoL assessment
Study NCT03799146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPlan 2.0
Description: MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
Study NCT03799146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting List
Description: Waiting List control group
Study NCT03939546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis EVC001
Description: Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)
Study NCT04612335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rate control
Description: Rate control drugs are administered to obtain symptom relief and a heart rate of \<110 bpm, followed by a 4-week telemonitoring period.
Study NCT04612335 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacological or electrical cardioversion
Description: Pharmacological or electrical cardioversion is performed to achieve restoration of sinus rhythm, either acutely or in a wait-and-see approach, all within 48 hours, and followed by a 4-week telemonitoring period.
Study NCT02196896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deprexis®
Description: Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
Study NCT02196896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information
Description: The patients receive online information about depression once a week for 90 days.
Study NCT03553901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure was performed before the injection onto GB30 point